TNXP (Tonix Pharmaceuticals Holding) ROCE %: -70.02% (As of Mar. 2026)

What is Tonix Pharmaceuticals Holding ROCE %?

Tonix Pharmaceuticals Holding TNXP +10.54% 41 ROCE % is -70.02% as of Mar. 2026. GuruFocus rates TNXP with a GF Score™ of 41/100 and a GF Value™ of $1.75 (Significantly Overvalued). The stock has 2 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Tonix Pharmaceuticals Holding's annualized ROCE % for the quarter that ended in Mar. 2026 was -70.02%.

Tonix Pharmaceuticals Holding (NAS:TNXP) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Tonix Pharmaceuticals Holding ROCE % Related Terms

Tonix Pharmaceuticals Holding ROCE % Historical Data

* Premium members only.

The historical data trend for Tonix Pharmaceuticals Holding's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tonix Pharmaceuticals Holding ROCE % Chart

Tonix Pharmaceuticals Holding Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

ROCE %

Get a 7-Day Free Trial

-60.03

-52.54

-69.01

-91.95

-63.41

Tonix Pharmaceuticals Holding Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
ROCE %	Get a 7-Day Free Trial															-37.21	-62.48	-64.07	-78.55	-70.02

41GF Score

Tonix Pharmaceuticals Holding Corp TNXP

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Tonix Pharmaceuticals Holding ROCE % Calculation

Tonix Pharmaceuticals Holding's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	-123.932	/	( ( (162.89 - 18.307)	+	(277.171 - 30.837) )	/ 2 )
	=	-123.932	/	( (144.583	+	246.334)	/ 2 )
	=	-123.932	/	195.4585
	=	-63.41 %

Tonix Pharmaceuticals Holding's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	-166.148	/	( ( (277.171 - 30.837)	+	(257.912 - 29.647) )	/ 2 )
	=	-166.148	/	( ( 246.334	+	228.265 )	/ 2 )
	=	-166.148	/	237.2995
	=	-70.02 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of -70.02% mean?

Tonix Pharmaceuticals Holding (TNXP) has a ROCE % of -70.02% as of Mar. 2026.

Is Tonix Pharmaceuticals Holding's ROCE % too high?

Tonix Pharmaceuticals Holding's current ROCE % is -70.02%. Overall, Tonix Pharmaceuticals Holding has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Tonix Pharmaceuticals Holding's ROCE % compare to UNCY and ENLV?

Tonix Pharmaceuticals Holding's ROCE % of -70.02% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Biotechnology company?

A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. Tonix Pharmaceuticals Holding's current ROCE % is -70.02%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Tonix Pharmaceuticals Holding stock overvalued right now?

Based on GuruFocus' analysis, Tonix Pharmaceuticals Holding (TNXP) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.75, compared to a current price of $13.11 — trading 649.1% above its estimated fair value. The current ROCE % is -70.02%. Tonix Pharmaceuticals Holding's overall GF Score™ is 41/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For Tonix Pharmaceuticals Holding (TNXP), the current ROCE % is -70.02% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Tonix Pharmaceuticals Holding (TNXP) Overvalued in 2026?

Based on GuruFocus' analysis, Tonix Pharmaceuticals Holding stock appears to be overvalued. The current stock price of $13.11 is trading 649.1% above its estimated GF Value™ of $1.75. GuruFocus considers Tonix Pharmaceuticals Holding to be Significantly Overvalued.

Key valuation signals for TNXP:

ROCE %: -70.02%
GF Value™: $1.75 vs. price of $13.11 (649.1% above fair value)
GF Score™: 41/100 with 2 warning signs

No single metric tells the full story. See the TNXP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Tonix Pharmaceuticals Holding Business Description

Industry Healthcare Biotechnology

Comparable Companies UNCY ENLV KRRO TNYA IMUX ABOS QTTB KPTI INDP MDWD VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Other Exchanges TPM0:Germany

Address 200 Connell Drive, Suite 3100, Berkeley Heights, NJ, USA, 07928

Website https://www.tonixpharma.com

Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.

41GF Score

Get the complete analysis for TNXP

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.11

Price

$1.75

GF Value

View TNXP Analysis

See ROCE % data for all stocks →